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2016 EMBO Chemical Biology Conference 
 
Satpal Virdee 
 
From August 31st- September 3rd the biennual EMBO Chemical Biology conference, 
hosted by the European Molecular Biology Laboratory (EMBL) in Heidelberg took place. The 
conference series has earned a well-deserved reputation as one of the finest meetings 
representing this discipline of life science research. A feature of this EMBO meeting is the 
consistency of the venue (EMBL is in a delightful location after all) and the organisers (Maja 
Kohn, John Overington and Carsten Schultz). This ensures familiarity and high 
complementarity with prior meetings. Indeed, a policy of the organising committee is that no 
speaker can be talk more than once so one should choose their opportunity wisely. 
The typical format was adopted where the conference is divided into sections based 
on topic and talks were a mixture of 4 keynote speakers and 38 speakers, the latter being 
invited or selected from abstracts. Almost 200 posters were also displayed throughout the 
meeting. 
 
Innovation in approaches to drug discovery 
 
The first talk of this introductory session was delivered by Gitte Neubauer (Cellzome). 
Cellzome is a successful EMBL spinout company which is now integrated within 
Glaxosmithkline (GSK). The founding principal of Cellzome is to employ mass proteomics and 
chemical biology to drive the drug discovery process, but also to establish target engagement 
thereby providing much needed insight into drug efficacy and toxicity. Gitte discussed a 
number of examples employing this strategy leading to the discovery of phosphoinositide 3-
kinase γ inhibitors, and their underappreciated off-targets[1]. The next speaker was Jason 
Gestwicki (UCSF). Jason discussed work that led to the successful identification of 
pharmacological chaperones that demonstrate potential for treating cataracts[2]. Cataracts 
arise from amyloid fibril formation in the lens of the eye. The solubility of the lens proteins 
(crystalins) is maintained by the presence of molecular chaperones known as αA-crystallin 
(cryAA) and αB-crystallin (cryAB). A disease model for cataracts and differential scanning 
fluorimetry were used as the basis of a screen for molecules that might stabilize the 
aggregation-prone mutant cryAB dimer.  A class of sterol compounds were found to have 
stabilizing activity and NMR experiments revealed that the compounds targeted the cryAB 
dimer interface, thus are likely to stabilize the dimeric state and maintain its solubility. 
Excitingly, cataract resolution was achieved in mice and in human ex vivo samples. The study 
demonstrates that the discovery of therapeutic agents against seemingly undruggable targets 
can be accelerated by the development of innovative screening approaches. Felix Hausch next 
presented recent work on the discovery of FK506-binding protein 51 (FKBP51) inhibitors that 
were selective over the highly homologous counterpart FKBP52[3]. Selectivity was imparted 
via an unanticipated induced fit mechanism. As FKBP51 is an established risk factor for stress-
related psychiatric disorders, this discovery potentially opens new avenues for novel 
antidepressant development. The following talk was delivered by Derek Tan (Memorial Sloan 
Kettering Cancer Center). Derek gave an overview of his labs work on the use of 
sulfonyladenosine-based inhibitors of adenylation enzymes. Adenylation enzymes are 
involved in a broad repertoire of cellular processes and are promising antibacterial and 
anticancer targets. Using mechanism- and structure-based design, 5′-O-(N-
salicylsulfamoyl)adenosine (salicyl-AMS) was shown to inhibit a key adenylation enzyme 
involved in siderophore biosynthesis in Mycobacterium tuberculosis, with demonstrated 
efficacy in mouse models of tuberculosis[4]. Olli Pentikainen (University of Jyväskylä) 
described virtual screening approaches that were associated with rapid execution and 
excellent success rate for the systems under study[5]. The next speaker was Stephanie 
Heinzlmeir from Bernhard Kuster’s lab (Technical University Munich). Stephanie reported the 
application of chemical proteomic approaches based on Kinobead technology for assessing 
the selectivity of kinase inhibitors[6]. Using this approach, Dasatinib was found to have high 
off-target activity towards the receptor tyrosine kinase EPHA2[7]. Structural biology enabled 
the elaboration of chemical analogues that were subsequently repurposed by profiling for 
enhanced EPHA2 selectivity, again using the Kinobead platform. This revealed that certain 
analogues had enhanced EPHA2 selectivity whilst retaining potency. This work showcased the 
described strategy as a viable approach for repurposing promiscuous kinase inhibitors and 
enhancing their selectivity via structure-based design.  
The first keynote talk rounded off the session which was delivered by Frances Arnold 
(California Institute of Technology). She delivered an engaging talk on her pioneering work on 
directed evolution. A goal of France’s lab is to create new enzymes and increase the repertoire 
of chemical transformations that can be genetically encoded. As an example, the ability of 
heme proteins to catalyze otherwise difficult to perform carbene- and nitrene-transfer 
reactions was demonstrated, together with enhancement of their activity via directed 
evolution[8].  
 
DNA/RNA/Chemical Epigenetics 
 
A new session began the following morning where Chuan He (University of Chicago) 
described his discovery of a novel class of RNA modifying enzymes.  The enzyme demethylases 
FTO and ALKBH5 were characterized and it was shown that reversible RNA methylation is a 
prevalent process that could serve a biological regulatory role analogous to epigenetic 
chromatin modification[9]. Indeed, it was shown that one such role is mRNA transcript 
synchronization and intriguingly, demethylation of ribosomal and transfer RNA are also 
observed. Andreas Marx next discussed the evolution of enzymes with new function such as 
DNA polymerases with reverse transcriptase activity[10]. Innovative chemical biology 
approaches for preparing proteins bearing site-specific post-translational modifications 
(PTMs) such as such poly(ADP)ribosylation were also discussed, together with methods for 
their imaging in cells[11]. 
Sophisticated semisynthetic strategies have been developed for the preparation of 
selectively modified chromatin thus serving as a powerful toolkit for addressing the histone 
code hypothesis[12]. However, the nucleosome building blocks of chromatin consist of dimers 
of the 4 core histone proteins. Contrary to physiological chromatin, conventional 
semisynthetic approaches furnish “symmetrically” modified octomeric nucleosomes 
containing the introduced modification on both of the protomers of a given histone. Beat 
Fierz (EPFL) described a novel approach to address this caveat by employing latent histone 
dimer fusions which could be tracelessly converted into native asymmetrically modified 
histones via protease treatment[13]. Andres Jaschke (Heidelberg University) introduced the 
unanticipated presence of 5’-modified RNA in bacteria and characterized a prokaryotic 
decapping enzyme[14]. Hening Lin (Cornell University) gave a talk on the unappreciated activity 
of the sirtuin family of deacetylases, their archetypal substrate being acetyl-lysine. However, 
Hening revealed that certain sirtuin family members, with negligible activity towards acetyl-
lysine, were highly active towards succinylated and fatty acylated lysine[15]. This led to the 
identification of these previously unidentified PTMs. Next, Masafumi Minoshima (Osaka 
University) spoke on probes of histone deacetylase activity[16], and Richard Hartley (University 
of Glasgow) presented his work on probes for detecting the reactive oxygen species, 
superoxide[17]. 
 
Protein profiling and target validation 
 
A fitting talk by Stephan Sieber (Technical University Munich) on activity-based protein 
profiling (ABPP) kicked off the next session. Stephan emphasized that currently only 3 major 
antibacterial targets are addressed pharmacologically, thus placing emphasis on the need to 
explore novel target space. Using the established fluorophosphonate-based ABPP platform 
for serine hydrolases, inhibitors of a novel bacterial target, the ClpP virulence regulator, were 
identified and selectivity profiled, leading to the discovery of series of phenyl ester inhibitors 
with improved selectivity and potency over previous beta-lactone-based scaffolds[18]. The 
following talk was delivered by Edward Tate (Imperial College London) describing the 
development and application of lipid-based chemical probes, such as “clickable” myristic acid 
analogues, for the identification of targets of myristoylation. Using these tools, proteome-
wide changes in lipidation in response to drug treatment could be assessed. Next, Satpal 
Virdee (University of Dundee) reported the development of a novel class of activity-based 
probes for profiling ubiquitin E3 ligases[19]. The utility of these probes was demonstrated by 
addressing the requirements, and their hierarchy, for the activation of the Parkinson’s disease 
(PD)-associated E3 ligase parkin. Biomarker potential of the probe technology for disease 
predisposition was also described.  Next, Robin Bon (University of Leeds) presented work on 
the brain-penetrable compound KHS101 which was found to induce self-destruction of 
gliobastoma muliforme cells. KHS101 derivatives bearing benzophenone photocrosslinking 
groups were subsequently employed to identify the target of KHS101 via chemical proteomic 
methods. 
The evening was rounded off with a second keynote talk delivered by Horst Kessler 
(Technical University Munich). Horst discussed his pioneering work on the development of 
peptide-based inhibitors and methods for enhancing their activity though methods such as 
cyclisation and modification of guanidine groups (N-methylation, N-alkylation, or N-
acylation)[20]. Selective inhibitors against distinct integrin subtypes were also presented and 
how these tools can be used to study the development of diseases that may involve specific 
integrin family members[21]. Horst also talked about combination therapies involving peptide 
inhibitors and the use of peptides in PET-based imaging[22]. 
 
Peptide and protein engineering     
 
This new topic began with a talk from Christian Heinis (EPFL). This talk focused on an 
innovative fusion of phage display and peptide modification to create bicyclic peptides. The 
technology involves phage-based selection of peptides which are rendered bicyclic through 
covalent modification with a small molecular aromatic core[23]. This produces chemical 
entities which demonstrate the potency and specificity of biologics but with pharmacokinetic 
properties more akin to small molecules. Christian described selection methods to derive 
highly potent inhibitors for a number of extracellular targets and approaches to optimise the 
technology were also discussed.  Next, Hiroaki Suga (The University of Tokyo) presented an 
alternative platform for generating libraries of peptide-based inhibitors termed Random non-
standard Peptide Integrated Discovery (RaPID). The technology involves in vitro translation of 
mRNA libraries which produces peptides containing non-proteinogenic amino acids that 
undergo spontaneous posttranslational cyclisation. As with Christians’ strategy, the peptides 
can be screened for binding against a protein target (e.g. the ubiquitin E3 ligase E6AP) and in 
this case the genotype-phenotype link is retained via tethering of the mRNA sequence to an 
obligate amino acid present in the peptide[24]. The following speaker was Yongjoo Bill Kim 
(Harvard University) from David Liu’s lab. The therapeutic potential of genome engineering 
approaches such as CRISPR/Cas9 technology is currently hampered by the off-target effects 
associated with the editing process. Conventional CRSIPR/Cas9 technology requires cutting of 
the DNA which can give rise to random insertions and deletions. The strategy presented by 
Yongjoo involved the use of catalytically inactive Cas9 fused to a cytidine deaminase. This 
enabled site-specific “base editing” where cytidine was converted to thymidine and this 
strategy was exemplified by correcting a number of disease-relevant point mutations[25]. 
Edward Lemke (EMBL, Germany) described approaches for the biorthogonal, dual-colour 
labelling of proteins in cells[26]. These were enabled by a combination of genetic code 
expansion and ultrafast “tetrazine ligation” methods. The utility of these approaches for 
super-resolution microscopy was also discussed[27]. Next, Anna Mapp spoke on strategies for 
targeting transient protein-protein interactions (PPIs). Taking transcriptional activator-
coactivator interactions as a system, Anna reported a strategy where particular 
conformations of transcriptional coactivators are engaged thereby modulating the assembly 
of active transactivator-coactivator complexes[28]. The next speaker was Wesley Robertson 
(Yale University) from Alanna Schepartz’s lab. Despite significant progress made in the area 
of genetic code expansion techniques, all non-canonical amino acids that can currently be 
incorporated into proteins typically retain a standard backbone. The ability to incorporate 
variants, such as -amino acids, could grant access to biological macromolecules with 
desirable properties such as enhanced proteolytic stability. Wesley presented work on 
evolved ribosomes that could incorporate -phenylalanine analogues into full-length protein 
thereby demonstrating the potential to prepare backbone perturbed polymeric materials 
with new function[29]. 
The next talk by Sanne Schoffelen (University of Copenhagen) described a novel 
method for site-selective protein labelling. This involved the introduction of azide 
functionality into proteins via a chemical diazotransfer reaction, which could be performed 
under aqueous and near-neutral pH conditions[30]. Intriguingly, the reaction appeared to be 
sensitive to the reduced pKa of N-terminal amino groups thereby rendering the approach site-
specific. This presents a valuable addition to protein-labelling toolkit by broadening the 
applicability of Click-based bioconjugations. 
 
Natural products/second messengers 
 
The first talk of this session was by Christopher Schofield (University of Oxford). An 
aspect of the talk was on prolyl hydroxylation carried out by prolyl hydrolase isoforms 1-3 
(PHD1-3) under normoxic conditions. PHD’s are attractive therapeutic targets and non-
isoform selective inhibitors are in clinical trials for the treatment of anaemia. The substrate 
of PHD’s are the N- and C-terminal oxygen-dependent degradation domains (NODD and 
CODD) present in HIFα isoforms. Chris reported PHD2 variants in erythrocytosis and cancer 
that were highly specific for NODD or CODD and the basis for this specificity was characterized 
by biophysical and cellular methods[31] .  Next, Dorothea Fiedler (Princeton University) spoke 
on the establishment of an enrichment and subsequent proteomic strategy for detecting 
substrates for the posttranslational modification, pyrophosphorylation[32]. 
Pyrophosphorylation occurs through enzyme-independent modification of existing Ser-
phosphorylated residues by reaction with inositol pyrophosphates. The importance of the 
enzymes involved in the biosynthesis of inositol pyrophosphates was highlighted thereby 
placing a need to determine what the substrates of pyrophosphorylation are and what 
cellular function this process might mediate. Next, Dowine de Bruijn (University of Groningen) 
introduced another strategy for chemoselective protein modification. The method involved 
the introduction of a terminal dehydroalanine residue into recombinant protein, which was 
then modified by oxidative Heck reaction.  Kalie Mix (UW-Masison) from Ronald Raines’ lab 
reported a novel approach for decorating the surface of proteins with ester-linked 
bioreversible cell penetrating tags by O-alkylation of carboxylic acids with diazo 
compounds[33]. The high esterase activity of mammalian cells subsequently hydrolyses the 
tags thereby proving valuable for cases where irreversible protein modification might 
compromise biological activity of the cargo. The following talk was by Miriam Fontanillo 
(EMBL Heidelberg) from Maja Köhn’s lab. Miriam highlighted the roles of phosphatases in 
diseases such as cancer and Alzheimer’s and how imparting inhibitor selectivity to one of the 
two main phosphatases (PP1 and PP2A) has remained challenging. A series of synthetic 
analogues of naturally occurring microcystins were prepared by peptide synthesis, in good 
yields, producing the first microcystin analogues with high selectivity for PP2A (282-fold)[34]. 
A thought-provoking third keynote talk followed, which was delivered by Giulio 
Superti-Furga (CeMM Center for Molecular Biology of the Austrian Academy of Sciences). This 
talk introduced the importance of solute carrier proteins (SLC’s) - transmembrane proteins 
responsible for the cellular import of the majority of chemical matter. A result of Giulio’s 
studies was the discovery that SLC’s are responsible for the uptake of a number of cytotoxic 
drugs. This was realized through screening haploid cell line libraries containing individual gene 
disruptions[35].  A particular example was the discovery of SLC35F2 as the SLC responsible for 
the uptake of the clinically evaluated anticancer compound YM155[36]. These discoveries 
place emphasis on the importance of identifying SLCs responsible for compound uptake in 
the early stages of drug discovery (e.g. to assess limitations that might arise from SLC 
heterogeneity). 
 
Light-based tools 
 
To start off the session, Robert Tampé (Johann Wolfgang Goethe-University Frankfurt) 
presented a new optochemical toolbox for the controlled assembly of receptor networks[37]. 
Additionally, specific labelling approaches, conducive to super-resolution live cell imaging, 
were also described. These involved the introduction of a fluorescent trisNTA probe which 
selectively labelled proteins bearing polyhistidine tags[38]. Jennifer Prescher (University of 
California, Irvine) next spoke on new tools for imaging cellular interactions. As examples, both 
caged luciferins and split luciferase were used to form the basis of cellular proximity 
sensors[39]. Jon Beck (University of Nebraska-Lincoln), a student in Cliff Stain’s lab, presented 
his work on sensors of tyrosine phosphatase activity with picomolar limits of detection[40] and 
Manuela Zaccolo (University of Oxford) discussed novel FRET-based reporters that detect 
compartmentalised cAMP with unprecedented spatial resolution. Dmytro Yushchenko (EMBL 
Heidelberg) from Carsten Schultz’s lab introduced tools for studying lipid signaling such as 
caged arachidonic acid derivatives and photoswitchable diacylglycerols (DAGs)[41]. The next 
talk was presented by James frank (LMU Munich) from Dirk Trauner’s lab. Therein, application 
of the previously described photoswitchable DAGs was employed which upon UV irradiation 
promote translocation of C1-domain-containing proteins to the plasma membrane. The 
ability to reverse the processes enabled the generation of oscillation patterns of DAG activity. 
This enabled the proteins protein kinase C and Munc13 to be placed under optical control 
thereby controlling vesicle release[41b]. The next talk was presented by Zbigniew Pianowski 
(KIT Karlsruhe) which described the use of photoswitchable hydrogels that had potential as a 
light-inducible delivery system for drugs or therapeutic oligonucleotides[42]. 
The closing talk was a keynote from Paul Wender (Stanford University). Paul’s talk 
summarized a large body of his inspirational work which was abound with translational 
implications. The first part described work towards eradicating HIV/AIDS. One aspect sought 
to address the challenges in eliminating persistent HIV reservoirs in latently infected immune 
cells. One strategy towards this was to induce HIV expression in these cells allowing their 
depletion through cytopathic effects[43]. This was achieved by synthesizing a series of 
prostratin analogs which had significantly higher potency over the promising existing 
preclinical lead.  
       
The excellent posters should also not be forgotten with nearly 200 being displayed 
throughout the conference. Numerous prizes were awarded which were sponsored by 
ChemBioChem (winners: Fleur Kleinpenning (Radboud University) and Christian Martin H 
(Institute for Scientific Research and Technology Services, Panama)), ACS Chemical Biology 
(winner: Joseph Rogers (University of Tokyo)), Royal Society of Chemistry (winner: Ulrik 
Bering Keiding (Aarhus University)) and Journal of Biological Chemistry (winner: Sabine Studer 
(ETH Zurich)). 
 
Summary 
 
Overall the quality of the chemical biology presented at the EMBO 2016 Chemical 
Biology conference was exceptional. Innovative approaches are enabling the targeting of 
previously considered undruggable proteins with small molecules. The perceived notion of 
many targets as being undruggable will surely continue to be unfounded as the field of 
chemical biology continues to flourish, thereby furnishing novel therapeutic targets for the 
future. However, the very nature of certain targets such as PPIs certainly do pose unique 
challenges but technologies such as the reported cyclic peptidic systems are perhaps one 
route to address this. The activity-based protein profiling platform continues to be a mainstay 
of many chemical biology programmes and extension to microorganisms and novel enzyme 
families, as described, will further its utility in identify novel enzyme family members and 
therapeutic targets. What was also clearly apparent was the level of precision with which we 
can now perturb cellular signaling pathways with innocuous methods such as light exposure. 
In particular, the use of diazobenzenes as reversible photoswitches is proving to be 
particularly valuable technology which is now routinely being used in creative ways.  Such 
methods are proving to be broadly applicable and so should continue to reveal insight into 
many biological systems.       
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